Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials

References

• Athyros VG, Boutari C, Karagiannis A. Ertugliflozin + metformin as a treatment option for type 2 diabetes. Expert Opin Pharmacother. 2021 Nov;22(16):2105–2111. doi: 10.1080/14656566.2021.1939676
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of clinical endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2020 Jan;26(1):107–139. doi: 10.4158/CS-2019-0472
   Google Scholar
• Draznin B, Aroda VR, Bakris G, et al.; American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical Care in diabetes-2022. Diabetes Care.2022 Jan 1;45(Suppl 1):S125–43.
   PubMedGoogle Scholar
• Draznin B, Aroda VR, Bakris G, et al.; American Diabetes Association Professional Practice Committee. 6. Glycemic targets: standards of medical Care in diabetes-2022. Diabetes Care.2022 Jan 1;45(Suppl 1):S83–96.
   PubMedGoogle Scholar
• Home, Resources, diabetes L with, Acknowledgement, FAQs, Contact. IDF diabetes atlas | tenth edition [internet]. [cited 2022 Aug 11]. Available from: https://diabetesatlas.org/
   Google Scholar
• Yang J. Ertugliflozin for treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2018 Aug;11(8):747–753. doi: 10.1080/17512433.2018.1503051
   PubMed Web of Science ®Google Scholar
• Scott LJ. Ertugliflozin in type 2 diabetes: a profile of its use. Drugs Ther Perspect. 2019 Aug;35(8):351–362. doi: 10.1007/s40267-019-00651-7
   Google Scholar
• Cowart K, Carris NW. Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial? Expert Opin Pharmacother. 2021 Feb;22(2):163–165. doi: 10.1080/14656566.2020.1822327
   PubMed Web of Science ®Google Scholar
• Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diab Obes Metab. 2019 Apr;21(4):1027–1036. doi: 10.1111/dom.13631
   PubMed Web of Science ®Google Scholar
• Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther Res Treat Educ diabetes Relat Disord. Diabetes Therapy. 2018 Feb;9(1):253–268. doi: 10.1007/s13300-017-0358-0
   PubMed Web of Science ®Google Scholar
• Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diab Obes Metab. 2018 May;20(5):1111–1120. doi: 10.1111/dom.13194
   PubMed Web of Science ®Google Scholar
• Pathak M, Parveen R, Khan P, et al. Impact of tofogliflozin on hepatic outcomes: a systematic review. Eur J Clin Pharmacol. 2023 Jul 18;79(10):1281–1290. doi: 10.1007/s00228-023-03537-w
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diab Obes Metab. 2018 Mar;20(3):530–540. doi: 10.1111/dom.13116
   PubMed Web of Science ®Google Scholar
• Aronson R, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diab Obes Metab. 2018 Jun;20(6):1453–1460. doi: 10.1111/dom.13251
   PubMed Web of Science ®Google Scholar
• Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diab Obes Metab. 2017 May;19(5):721–728. doi: 10.1111/dom.12888
   PubMed Web of Science ®Google Scholar
• McNeill AM, Davies G, Kruger E, et al. Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: a systematic literature review and network meta-analysis. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2019 Apr;10(2):473–491. doi: 10.1007/s13300-019-0566-x
   Google Scholar
• Fediuk D, Mandema J, Sweeney K, et al. Comparative efficacy of Ertugliflozin (ERTU) vs. Other sodium-glucose cotransporter 2 inhibitors (SGLT2i): model-based meta-analysis (MBMA) of HbA1c lowering. Diabetes. 1222 [1 Jun 2019];68(Supplement_1):1222–. doi: 10.2337/db19-1222-P
   Google Scholar
• Patel S, Hickman A, Frederich R, et al. Safety of Ertugliflozin in patients with type 2 diabetes mellitus: Pooled analysis of Seven Phase 3 randomized controlled trials. Diabetes Ther. 2020 Jun;11(6):1347–1367. doi: 10.1007/s13300-020-00803-3
   PubMed Web of Science ®Google Scholar
• Huang J, Xiong S, Ding S, et al. Safety of Ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with conventional therapy at different periods: a meta-analysis of randomized controlled trials. J Diabetes Res. 2020 Dec 14;2020:9704659. doi: 10.1155/2020/9704659
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S. Cochrane handbook for systematic Reviews of interventions 4.2.6 [updated September 2006]. In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd.; 2006. p. 674 . (Cochrane Book Series; 4).
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898
   PubMedGoogle Scholar
• Amin NB, Wang X, Jain SM, et al. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diab Obes Metab. 2015 Jun;17(6):591–598. doi: 10.1111/dom.12460
   PubMed Web of Science ®Google Scholar
• Ji L, Liu Y, Miao H, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diab Obes Metab. 2019 Jun;21(6):1474–1482. doi: 10.1111/dom.13681
   PubMed Web of Science ®Google Scholar
• Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2018 Feb;9(1):49–66. doi: 10.1007/s13300-017-0337-5
   Google Scholar
• Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diab Obes Metab. 2018 Mar;20(3):520–529. doi: 10.1111/dom.13103
   PubMed Web of Science ®Google Scholar
• Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2018 Feb;9(1):193–207. doi: 10.1007/s13300-017-0354-4
   Google Scholar
• Budoff MJ, Davis TME, Palmer AG, et al. Efficacy and safety of Ertugliflozin in patients with type 2 diabetes inadequately controlled by metformin and sulfonylurea: a Sub-study of VERTIS CV. Diabetes Ther Res Treat Educ diabetes Relat Disord. Diabetes Therapy. 2021 May;12(5):1279–1297. doi: 10.1007/s13300-021-01033-x
   PubMed Web of Science ®Google Scholar
• Strojek K, Pandey AS, Dell V, et al. Efficacy and safety of Ertugliflozin in patients with diabetes mellitus inadequately controlled by sulfonylurea monotherapy: a substudy of VERTIS CV. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2021 Apr;12(4):1175–1192. doi: 10.1007/s13300-021-01018-w
   Google Scholar
• Lingvay I, Greenberg M, Gallo S, et al. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: a VERTIS CV substudy. Diab Obes Metab. 2021 Jul;23(7):1640–1651. doi: 10.1111/dom.14385
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013 Apr;41(2):72–84. doi: 10.3810/hp.2013.04.1020
   PubMedGoogle Scholar
• Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019;79(10):1135–1146. doi: 10.1007/s40265-019-01148-3
   PubMed Web of Science ®Google Scholar
• Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2017 Aug;13(4):405–423. doi: 10.2174/1573399812666160613113556
   PubMed Web of Science ®Google Scholar
• Ferrannini G, Hach T, Crowe S, et al. Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Sep;38(9):1730–1735. doi: 10.2337/dc15-0355
   PubMed Web of Science ®Google Scholar
• Napolitano A, Miller S, Murgatroyd PR, et al. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J Clin Transl Endocrinol. 2014 Mar;1(1):e3–8. doi: 10.1016/j.jcte.2013.12.001
   PubMedGoogle Scholar
• Boeder S, Edelman SV. Sodium‐glucose co‐transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials. Diab Obes Metab. 2019 Apr;21(Suppl 2):62–77. doi: 10.1111/dom.13749
   PubMedGoogle Scholar
• Fishman B, Shlomai G, Twig G, et al. Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents. Cardiovasc Diabetol. 2019 Sep 25;18(1):124. doi: 10.1186/s12933-019-0929-7
   PubMed Web of Science ®Google Scholar
• Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–230. doi: 10.1007/s40265-019-1057-0
   PubMed Web of Science ®Google Scholar